Cargando…

The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis

The impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains uncertain, which has been the focus of studies on the management of epithelial ovarian cancer (EOC). To investigate the efficacy of bevacizumab combinations with different regimens in the treatment of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Guanyu, Ye, Lixiang, Liu, Guifen, An, Jian, Sehouli, Jalid, Sun, Pengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788992/ https://www.ncbi.nlm.nih.gov/pubmed/29416352 http://dx.doi.org/10.2147/OTT.S155581

Ejemplares similares

Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer
por: Sun, PengMing, et al.
Publicado: (2018)

Key regulator of cellular metabolism, estrogen-related receptor α, a new therapeutic target in endocrine-related gynecological tumor
por: Liu, GuiFen, et al.
Publicado: (2018)

Immunohistochemical Analysis of PGC-1α and ERRα Expression Reveals Their Clinical Significance in Human Ovarian Cancer
por: Huang, Xiqi, et al.
Publicado: (2020)

Epithelial Ovarian Cancer: Focus on Targeted Therapy
por: Markman, M., et al.
Publicado: (2010)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities
por: Liu, GuiFen, et al.
Publicado: (2020)

ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer
por: Huang, Meimei, et al.
Publicado: (2020)

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
por: Mao, XiaoDan, et al.
Publicado: (2019)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Lipid reprogramming induced by the TFEB-ERRα axis enhanced membrane fluidity to promote EC progression
por: Mao, Xiaodan, et al.
Publicado: (2022)

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells
por: Jun, Jong Hwa, et al.
Publicado: (2016)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA
por: Sun, PengMing, et al.
Publicado: (2018)

Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
por: Nagai, Toshihiro, et al.
Publicado: (2014)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
por: Yokoyama, Y, et al.
Publicado: (2003)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer
por: Kreienbring, Katrin, et al.
Publicado: (2016)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery(∗): A Prospective Substudy of a Randomized Controlled Trial
por: Hunsicker, Oliver, et al.
Publicado: (2015)

Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells
por: Brar, Vikram S., et al.
Publicado: (2010)

Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab
por: Wang, Donghyun, et al.
Publicado: (2014)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
por: Passler, Mona, et al.
Publicado: (2019)

Evaluation of Knowledge and Attitude Toward HPV and Vaccination Among Medical Staff, Medical Students, and Community Members in Fujian Province
por: Yu, Chang, et al.
Publicado: (2020)

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens
por: Schossig, Paul, et al.
Publicado: (2023)

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
por: Sehouli, Jalid, et al.
Publicado: (2021)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
por: Marchetti, Claudia, et al.
Publicado: (2015)

Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia
por: Sun, Pengming, et al.
Publicado: (2016)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
por: Chung, Eun Jee, et al.
Publicado: (2011)

Concentration of Vascular Endothelial Growth Factor After Intracameral Bevacizumab Injection in Eyes With Neovascular Glaucoma
por: Lim, Tae Hoon, et al.
Publicado: (2009)

Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
por: Fernando Arevalo, J.
Publicado: (2013)

Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration
por: Mayer, Christine, et al.
Publicado: (2016)

Decreasing the ratio of matriptase/HAI-1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer
por: Sun, Pengming, et al.
Publicado: (2016)

Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells
por: Sun, Pengming, et al.
Publicado: (2018)

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
por: Wu, Yu Shen, et al.
Publicado: (2016)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
por: Guo, Fang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b08upf2sgh9qlbpbv21naqms93